In CLL, CD160 has been shown to mediate PI3K-dependent regulation of cell activation, and positive regulation (upregulation) of Bcl-2 and Bcl-XL proteins. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.